The FDA cleared PrecivityAD2, a blood test designed to help evaluate Alzheimer’s disease by detecting amyloid pathology. Developed and validated from technology pioneered at Washington University School of Medicine in St. Louis, PrecivityAD2 is positioned as an aid to clinical assessment rather than a stand-alone diagnostic. For biotech, the clearance adds momentum to a growing category of blood-based biomarkers and may accelerate downstream trial enrichment and patient stratification strategies across neurology programs.